AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims

- 1. 6. (Canceled)
- 7. (Currently Amended) <u>A</u> [[The]] method for predicting pregnancy-induced hypertension according to claim 5, which comprises measuring the level of human lipocalin-type prostaglandin D synthase in a body fluid sample collected from a subject and comparing the measured value with a cut-off value that is determined from measured values of human lipocalin-type prostaglandin D synthase in body fluid samples collected from normal pregnant women not exhibiting symptoms of hypertension, proteinuria, and edema and not thought to be clinically affected with PIH and/or pregnant women with pregnancy-induced hypertension, wherein it is determined that the risk of developing PIH in the future is high when the measured value of human lipocalin-type prostaglandin D synthase is higher than the cut-off value.
- 8. 10. (Canceled)
- 11. (Currently Amended) The method for predicting pregnancy-induced hypertension according to elaim 5 claim 7, wherein the level of human lipocalin-type prostaglandin D synthase in a body fluid sample is measured by an immunological assay method selected from the group consisting of an enzyme immunoassay method, a radio-immunoassay method, a latex agglutination assay method, and a fluorescence immunoassay method.
- 12. (Canceled)
- 13. (Currently Amended) The method according to elaim 1 claim 7, wherein the body fluid sample is blood.
- 14. (Currently Amended) The method according to elaim 1 claim 7, wherein the body fluid sample is urine.

- 15. (Canceled)
- 16. (New) The method according to claim 11, wherein the body fluid sample is blood.
- 17. (New) The method according to claim 11, wherein the body fluid sample is urine.